167 related articles for article (PubMed ID: 20413296)
1. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines.
Sasada T; Komatsu N; Suekane S; Yamada A; Noguchi M; Itoh K
Eur J Cancer; 2010 Jun; 46(9):1514-9. PubMed ID: 20413296
[TBL] [Abstract][Full Text] [Related]
2. [Current status and future perspective of cancer vaccine development].
Sasada T; Itoh K
Gan To Kagaku Ryoho; 2011 Apr; 38(4):503-8. PubMed ID: 21498975
[TBL] [Abstract][Full Text] [Related]
3. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
4. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
Mosolits S; Nilsson B; Mellstedt H
Expert Rev Vaccines; 2005 Jun; 4(3):329-50. PubMed ID: 16026248
[TBL] [Abstract][Full Text] [Related]
5. Recent developments in therapeutic cancer vaccines.
Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
[TBL] [Abstract][Full Text] [Related]
6. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
7. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
8. [Cancer vaccines].
Kyte JA
Tidsskr Nor Laegeforen; 2006 Nov; 126(22):2969-73. PubMed ID: 17117197
[TBL] [Abstract][Full Text] [Related]
9. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.
Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697
[TBL] [Abstract][Full Text] [Related]
10. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
11. Roadmap to a better therapeutic tumor vaccine.
Emens LA
Int Rev Immunol; 2006; 25(5-6):415-43. PubMed ID: 17169782
[TBL] [Abstract][Full Text] [Related]
12. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
13. Tumor antigens as surrogate markers and targets for therapy and vaccines.
Dalgleish A; Pandha H
Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer vaccines: promise for the future or pipe dream?
Mittendorf EA; Peoples GE; Singletary SE
Cancer; 2007 Oct; 110(8):1677-86. PubMed ID: 17763371
[TBL] [Abstract][Full Text] [Related]
16. Cancer vaccines: between the idea and the reality.
Finn OJ
Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
[TBL] [Abstract][Full Text] [Related]
17. Current developments with peptide-based human tumor vaccines.
Khazaie K; Bonertz A; Beckhove P
Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
[TBL] [Abstract][Full Text] [Related]
18. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention.
Vonderheide RH
Discov Med; 2007 Aug; 7(39):103-8. PubMed ID: 18093471
[TBL] [Abstract][Full Text] [Related]
19. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
[TBL] [Abstract][Full Text] [Related]
20. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE
Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
